Item 2.02. Results of Operations and Financial Condition.
On
Item 7.01. Regulation FD Disclosure.
The information set forth under Item 2.02 of this Current Report on Form 8-K is incorporated by reference herein.
On
The information included in Item 2.02 and the information included or incorporated in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. 99.1 Presentation byLeonard S. Schleifer , M.D., Ph.D., President and Chief Executive Officer ofRegeneron Pharmaceuticals, Inc. , and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer ofRegeneron Pharmaceuticals, Inc. , at the 38th AnnualJ.P. Morgan Healthcare Conference .
--------------------------------------------------------------------------------
© Edgar Online, source